share_log

Virpax Pharmaceuticals | 8-K: Current report

Virpax Pharmaceuticals | 8-K: Current report

Virpax制药 | 8-K：重大事件
美股sec公告 ·  04/30 07:40
Moomoo AI 已提取核心信息
Virpax Pharmaceuticals, Inc., a Delaware-based company, announced on April 30, 2024, the results of a Maximum Tolerated Dose (MTD) study for its drug Probudur, conducted on Sprague-Dawley rats. Probudur is a long-acting liposomal bupivacaine formulation designed for post-operative pain management, aiming to reduce or eliminate the need for opioids. The study aimed to determine the MTD of Probudur, both alone and in combination with free bupivacaine, when administered as a single subcutaneous injection. The results indicated that all doses of Probudur were well-tolerated, with no significant effects on body weight, clinical chemistry, hematology, or coagulation. Histopathology showed minimal to moderate changes at the injection site, with slightly more pronounced effects at higher doses. The company plans to file an Investigational New Drug Application (IND) for Probudur by the end of the year. Virpax is also developing other non-addictive pain management products and has cooperative research and development agreements with the NIH and DOD.
Virpax Pharmaceuticals, Inc., a Delaware-based company, announced on April 30, 2024, the results of a Maximum Tolerated Dose (MTD) study for its drug Probudur, conducted on Sprague-Dawley rats. Probudur is a long-acting liposomal bupivacaine formulation designed for post-operative pain management, aiming to reduce or eliminate the need for opioids. The study aimed to determine the MTD of Probudur, both alone and in combination with free bupivacaine, when administered as a single subcutaneous injection. The results indicated that all doses of Probudur were well-tolerated, with no significant effects on body weight, clinical chemistry, hematology, or coagulation. Histopathology showed minimal to moderate changes at the injection site, with slightly more pronounced effects at higher doses. The company plans to file an Investigational New Drug Application (IND) for Probudur by the end of the year. Virpax is also developing other non-addictive pain management products and has cooperative research and development agreements with the NIH and DOD.
总部位于特拉华州的公司Virpax Pharmaceuticals, Inc. 于2024年4月30日公布了对Sprague-Dawley大鼠进行的最大耐受剂量（MTD）研究的结果。Probudur 是一种长效脂质体布比卡因配方，专为术后疼痛管理而设计，旨在减少或消除对阿片类药物的需求。该研究旨在确定单独使用或与游离布比卡因联合使用时作为单次皮下注射时Probudur的MTD。结果表明，所有剂量的Probudur均具有良好的耐受性，对体重、临床化学、血液学或凝血没有显著影响。组织病理学显示，注射部位的变化微乎其微，较高剂量时效果稍显明显。该公司计划在今年年底之前提交Probudur的研究性新药申请（IND）。Virpax还在开发其他非成瘾性疼痛管理产品，并与美国国立卫生研究院和国防部签订了合作研发协议。
总部位于特拉华州的公司Virpax Pharmaceuticals, Inc. 于2024年4月30日公布了对Sprague-Dawley大鼠进行的最大耐受剂量（MTD）研究的结果。Probudur 是一种长效脂质体布比卡因配方，专为术后疼痛管理而设计，旨在减少或消除对阿片类药物的需求。该研究旨在确定单独使用或与游离布比卡因联合使用时作为单次皮下注射时Probudur的MTD。结果表明，所有剂量的Probudur均具有良好的耐受性，对体重、临床化学、血液学或凝血没有显著影响。组织病理学显示，注射部位的变化微乎其微，较高剂量时效果稍显明显。该公司计划在今年年底之前提交Probudur的研究性新药申请（IND）。Virpax还在开发其他非成瘾性疼痛管理产品，并与美国国立卫生研究院和国防部签订了合作研发协议。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息